# US 2024/0189322 A1 · TROPOMYOSIN-RELATED KINASE (trk) INHIBITORS

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189322 A1
- Document ID: US20240189322A1
- Status: Published application
- Kind: A1
- Application number: 18/516,091
- Filed: 2023-11-21
- Published: 2024-06-13
- Earliest claimed: 2013-12-10
- Assignees: Genzyme Corporation
- Applicants: Genzyme Corporation
- Inventors: John L. KANE, JR.; Gloria MATTHEWS; Markus METZ; Michael KOTHE; Jinyu LIU; Andrew SCHOLTE
- Web page: https://patentgrep.com/patent/US20240189322A1

## CPC

- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/66: Phosphorus compounds
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 471/08: Bridged systems
- C07D 471/10: Spiro-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 487/08: Bridged systems
- C07D 487/10: Spiro-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07F 9/5022: {Aromatic phosphines (P-C aromatic linkage)}
- C07F 9/6506: having the nitrogen atoms in positions 1 and 3
- C07F 9/65583: {each of the hetero rings containing nitrogen as ring hetero atom}
- C07F 9/6561: containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).

## Claims

### Claim at position 1

1-57. (canceled)

### Claim 58

A method of treating a condition selected from the group consisting of osteoarthritis and pain in a patient, comprising administering to a patient in need thereof a pharmaceutical composition comprising a compound of Formula (II) in order to treat the condition, wherein Formula II is represented by:
or a pharmaceutically acceptable salt thereof, wherein:
n is 1, 2, or 3;
m is 0, 1, 2, or 3;
Q1 is (C2-C9)heteroaryl optionally substituted by one to four groups selected from (C1-C10)alkyl, (C2-C9)heteroalkyl, (C3-C10)cycloalkyl, (C2-C9)heterocycloalkyl, (C1-C10)alkylamine, (C1-C10)alkyl-C(O)O—, (C1-C10)alkyl-O—, —OH, or —NH2;
Q2 is (C6-C14)aryl, (C2-C9)heteroaryl, (C3-C10)cycloalkyl, or (C2-C9)heterocycloalkyl, wherein the (C6-C14)aryl, (C2-C9)heteroaryl, (C3-C10)cycloalkyl, or (C2-C9)heterocycloalkyl is optionally substituted by one to four groups selected from (C1-C10)alkyl, (C2-C9)heteroalkyl, (C3-C10)cycloalkyl, (C2-C9)heterocycloalkyl, (C1-C10)alkylamine, (C1-C10)alkyl-C(O)O—, (C1-C10)alkyl-O—, —OH, or —NH2;
X is CH, N, or CR9, wherein R9 is (C1-C10)alkyl;
R1 is (C1-C10)alkylamine or NH2; and
R2 is (C1-C10)alkylamine or (C1-C10)alkyl-O—.

### Claim 59 (depends on 58)

The method of claim 58, wherein Q1 is (C2-C9)heteroaryl substituted by (C1-C10)alkyl; and Q2 is (C6-C14)aryl substituted by (C1-C10)alkyl-O—.

### Claim 60 (depends on 59)

The method of claim 59, wherein X is N; and R1 is NH2.

### Claim 61 (depends on 60)

The method of claim 60, wherein R2 is (C1-C10)alkyl-O—.

### Claim 62 (depends on 58)

The method of claim 58, wherein the pharmaceutical composition comprises
or a pharmaceutically acceptable salt thereof.

### Claim 63 (depends on 58)

The method of claim 58, wherein the pharmaceutical composition comprises

### Claim 64 (depends on 58)

The method of claim 58, wherein the condition is pain.

### Claim 65 (depends on 62)

The method of claim 62, wherein the condition is pain.

### Claim 66 (depends on 63)

The method of claim 63, wherein the condition is pain.

### Claim 67 (depends on 58)

The method of claim 58, wherein the condition is post-operative pain.

### Claim 68 (depends on 63)

The method of claim 63, wherein the condition is post-operative pain.

### Claim 69 (depends on 58)

The method of claim 58, wherein the condition is osteoarthritis knee pain.

### Claim 70 (depends on 62)

The method of claim 62, wherein the condition is osteoarthritis knee pain.

### Claim 71 (depends on 58)

The method of claim 58, wherein the administering comprises injection for local delivery.

### Claim 72 (depends on 63)

The method of claim 63, wherein the administering comprises injection for local delivery.

### Claim 73 (depends on 70)

The method of claim 70, wherein the administering comprises injection for local delivery.

### Claim 74

A method of treating pain associated with osteoarthritis in a patient, comprising administering to a patient in need thereof a pharmaceutical composition comprising a compound of Formula (II) in order to treat the pain associated with osteoarthritis, wherein Formula II is represented by:
or a pharmaceutically acceptable salt thereof, wherein:
n is 1, 2, or 3;
m is 0, 1, 2, or 3;
Q1 is (C2-C9)heteroaryl optionally substituted by one to four groups selected from (C1-C10)alkyl, (C2-C9)heteroalkyl, (C3-C10)cycloalkyl, (C2-C9)heterocycloalkyl, (C1-C10)alkylamine, (C1-C10)alkyl-C(O)O—, (C1-C10)alkyl-O—, —OH, or —NH2;
Q2 is (C6-C14)aryl, (C2-C9)heteroaryl, (C3-C10)cycloalkyl, or (C2-C9)heterocycloalkyl, wherein the (C6-C14)aryl, (C2-C9)heteroaryl, (C3-C10)cycloalkyl, or (C2-C9)heterocycloalkyl is optionally substituted by one to four groups selected from (C1-C10)alkyl, (C2-C9)heteroalkyl, (C3-C10)cycloalkyl, (C2-C9)heterocycloalkyl, (C1-C10)alkylamine, (C1-C10)alkyl-C(O)O—, (C1-C10)alkyl-O—, —OH, or —NH2;
X is CH, N, or CR9, wherein R9 is (C1-C10)alkyl;
R1 is (C1-C10)alkylamine or NH2; and
R2 is (C1-C10)alkylamine or (C1-C10)alkyl-O—.

### Claim 75 (depends on 74)

The method of claim 74, wherein Q1 is (C2-C9)heteroaryl substituted by (C1-C10)alkyl; and Q2 is (C6-C14)aryl substituted by (C1-C10)alkyl-O—.

### Claim 76 (depends on 75)

The method of claim 75, wherein X is N; and R1 is NH2.

### Claim 77 (depends on 76)

The method of claim 76, wherein R2 is (C1-C10)alkyl-O—.

### Claim 78 (depends on 74)

The method of claim 74, wherein the pharmaceutical composition comprises
or a pharmaceutically acceptable salt thereof.

### Claim 79 (depends on 74)

The method of claim 74, wherein the administering comprises injection for local delivery.

### Claim 80 (depends on 78)

The method of claim 78, wherein the administering comprises injection for local delivery.

### Claim 81

A method of treating pain associated with osteoarthritis in a patient, comprising administering to a patient in need thereof a pharmaceutical composition comprising the following compound
in order to treat the pain associated with osteoarthritis.

### Claim 82 (depends on 81)

The method of claim 81, wherein the pain associated with osteoarthritis is osteoarthritis knee pain.

### Claim 83 (depends on 81)

The method of claim 81, wherein the administering comprises injection for local delivery.

### Claim 84 (depends on 82)

The method of claim 82, wherein the administering comprises injection for local delivery.
